A vibrating mattress and a nitric oxide pill could eliminate Alzheimer’s proteins from the brain

The blood levels of beta-amyloid 42 increased on average by 35% in healthy adults who spent 40 minutes on a gently vibrating mattress while taking two sublingual nitric oxide-releasing pills. This result, taken from Vesa Kiviniemi of the University of Oulu and colleagues, constitutes the central finding of the study and requires immediate context to make sense.

Beta-amyloid 42 is a protein involved in normal neuronal signaling, but when it misfolds and clumps together in brain tissue, these aggregates are associated with Alzheimer’s disease.

The brain has a waste disposal network and this study attempted to tune it

The glymphatic system removes metabolic waste through fluid channels around blood vessels in the brain, and researchers have sought to amplify this process.

THE glymphatic system is a network of fluid-filled channels surrounding cerebral blood vessels that carry metabolic waste out of the brain. This works in part by the rhythmic widening and narrowing of these vessels, which send waste-laden fluids toward elimination.

The mechanism proposed by Kiviniemi is based on two axes. Gentle vibrations throughout the body can activate the Piezo1 protein in the muscle cells of the vessel walls, a link identified in previous animal research. Nitric oxide promotes vessel dilation and together, the researchers suggest, the two effects amplify the pulsation that drives glymphatic clearance.

When participants received only the mattress or only the pills, the apparent effect on fluid movement was less than half that produced by the combined intervention.

Higher blood levels could mean export. Or anything else.

An alternative explanation from an outside researcher complicates the team’s interpretation.

Kiviniemi’s team interprets the increase in circulating beta-amyloid 42 as evidence that more of the protein has moved from the brain into the bloodstream. Christopher Brown, of the University of Southampton, proposed a different reading: the liver might simply have broken down the protein more slowly than usual, which would also produce a higher blood concentration without any change in brain clearance.

Brown suggested that injecting tracers into the spinal fluid to directly track lymphatic flow could help reduce this uncertainty in future work.

The study was small, healthy and short

None of the 29 participants had a diagnosis of Alzheimer’s or cognitive impairment.

Six participants reported mild nausea or headache after the combined intervention. Because the trial did not include a placebo pill, it is not currently possible to separate actual side effects from expectations, and future trials should add this control.

It is not a treatment for Alzheimer’s disease

The study measured an acute biomarker change in healthy adults, not a reduction in symptoms or disease risk.

No reduction in Alzheimer’s symptoms, brain amyloid plaques or dementia risk was measured. Clinically meaningful therapy would require reproducible effects in people with mild cognitive impairment or Alzheimer’s disease. It would also require lasting changes in brain pathology and measurable gains in memory or problem solving.

Nitric oxide lowers blood pressure. Don’t try this at home.

Kiviniemi warned that nitric oxide’s effect on blood pressure carries a serious risk for some people.

Kiviniemi warned that nitric oxide can lower blood pressure and that, for anyone already suffering from hypotension, taking a pill that releases nitric oxide could lead to loss of consciousness. Nitric oxide supplements and inhalation of large doses of carbon dioxide should not be attempted outside of a clinical setting, and this intervention does not establish that a commercial product is safe or effective.

Other researchers are looking for the same system

Glymphatic research extends well beyond vibrating mattresses.

Other experimental approaches being studied include ultrasound, pink noise and intermittent inhalation of high concentrations of carbon dioxide. Brown noted that pursuing multiple strategies improves the chances that at least one of them will ultimately produce a clinically useful tool.

Next trial will test people who actually have the disease

The results of a planned study involving 60 people could clarify whether the effect holds up in the population that needs it most.

Kiviniemi’s team hopes to test the combined approach in 60 people suffering from mild cognitive impairment or Alzheimer’s disease. If this trial produces a positive result, a longer study of several months could evaluate whether repeated treatment affects memory and problem solving.